Designing an integrated drug benefit for the elderly.

Area of Science:

• Health Economics
• Geriatric Medicine
• Pharmaceutical Policy

Background:

• Elderly individuals face significant financial strain due to high out-of-pocket prescription drug expenses.
• Current healthcare systems may not adequately address the comprehensive needs of older adults regarding medication costs and overall care.

Purpose of the Study:

• To evaluate the financial feasibility and potential impact of a coordinated, systems-based pharmaceutical benefit for the elderly.
• To explore alternative models for pharmaceutical benefits that improve quality of care without prohibitive national costs.

Main Methods:

• Analysis of financial models for a stand-alone versus integrated pharmaceutical benefit.
• Examination of cost-sharing mechanisms, premium structures, and market-driven price reduction strategies.
• Assessment of potential cost savings through integrated managed care and improved patient outcomes.

Main Results:

• A stand-alone pharmaceutical benefit could incur substantial national costs without guaranteed improvements in elderly care quality.
• A systems-based pharmaceutical benefit is presented as a financially viable approach.
• Financial feasibility is achievable through a mix of premiums, cost sharing, price negotiations, and integrated care savings.

Conclusions:

• Integrating pharmaceutical benefits with existing medical benefits is crucial for optimizing care for the elderly.
• A coordinated, systems-based approach offers a financially feasible pathway to address high prescription drug costs and enhance care quality for older Americans.
• Policy interventions should focus on integrated models rather than fragmented pharmaceutical benefits.